Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3911 ARTÍCULOS , VIENDO DEL 496 AL 510

Functions and characteristics of PINK1 and Parkin in cancer

Matsuda S, Nakanishi A, Minami A, Wada Y, Kitagishi Y.

Front Biosci (Landmark Ed). 2015 Jan 1;20(3):491-501. doi: 10.2741/4321.

Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation

Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C, Lin X, Bammler TK, Stewart T, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Zhang J.

Mol Cell Proteomics. 2015 Mar;14(3):544-55. doi: 10.1074/mcp.M114.040576. Epub 2015 Jan 2.

Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory

Halliday M, Mallucci GR.

Neuropathol Appl Neurobiol. 2015 Jun;41(4):414-27. doi: 10.1111/nan.12211.

Beyond mitophagy: cytosolic PINK1 as a messenger of mitochondrial health

Steer EK, Dail MK, Chu CT.

Antioxid Redox Signal. 2015 Apr 20;22(12):1047-59. doi: 10.1089/ars.2014.6206. Epub 2015 Feb 18.

A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders

Mazibuko Z, Choonara YE, Kumar P, Du Toit LC, Modi G, Naidoo D, Pillay V.

J Pharm Sci. 2015 Apr;104(4):1213-29. doi: 10.1002/jps.24322. Epub 2015 Jan 5.

Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension

Keating GM.

Drugs. 2015 Feb;75(2):197-206. doi: 10.1007/s40265-014-0342-1.

Catechol-O-methyltransferase inhibitors in Parkinson's disease

Müller T.

Drugs. 2015 Feb;75(2):157-74. doi: 10.1007/s40265-014-0343-0.

Deep brain stimulation for Parkinson disease: the 2014 Lasker-DeBakey Clinical Medical Research Award

Rousseaux MW, Zoghbi HY.

JAMA Neurol. 2015 Mar;72(3):259-60. doi: 10.1001/jamaneurol.2014.4109.

Association of MTHFR C677T with total homocysteine plasma levels and susceptibility to Parkinson's disease: a meta-analysis

Zhu Y, Zhu RX, He ZY, Liu X, Liu HN.

Neurol Sci. 2015 Jun;36(6):945-51. doi: 10.1007/s10072-014-2052-6. Epub 2015 Jan 7.

Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study

Abbruzzese G, Barone P, Ceravolo R, Fabbrini G, Lessi P, Ori A, Simoni L, Tinazzi M, Antonini A.

Neurol Sci. 2015 Jun;36(6):935-43. doi: 10.1007/s10072-014-2060-6. Epub 2015 Jan 7.

Genetic control of midbrain dopaminergic neuron development

Blaess S, Ang SL.

Wiley Interdiscip Rev Dev Biol. 2015 Mar-Apr;4(2):113-34. doi: 10.1002/wdev.169. Epub 2015 Jan 6.

A Randomized Controlled Trial to Reduce Falls in People With Parkinson's Disease

Morris ME, Menz HB, McGinley JL, Watts JJ, Huxham FE, Murphy AT, Danoudis ME, Iansek R.

Neurorehabil Neural Repair. 2015 Sep;29(8):777-85. doi: 10.1177/1545968314565511. Epub 2015 Jan 7.

An algorithmic approach to the evaluation and treatment of olfactory disorders

Daramola OO, Becker SS.

Curr Opin Otolaryngol Head Neck Surg. 2015 Feb;23(1):8-14. doi: 10.1097/MOO.0000000000000118.

Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle

Sardi SP, Cheng SH, Shihabuddin LS.

Prog Neurobiol. 2015 Feb;125:47-62. doi: 10.1016/j.pneurobio.2014.12.001. Epub 2015 Jan 6.

Does response inhibition have pre- and postdiagnostic utility in Parkinson's disease?

MacDonald HJ, Byblow WD.

J Mot Behav. 2015;47(1):29-45. doi: 10.1080/00222895.2014.941784.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias